Stojiljković, Bratislav

Link to this page

Authority KeyName Variants
b2267392-20ca-42b9-bdd2-0582f40f8876
  • Stojiljković, Bratislav (4)
Projects

Author's Bibliography

Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Demajo, Miroslav; Mandušić, Vesna; Dimitrijević, Bogomir B.

(2016)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Demajo, Miroslav
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1327
AB  - We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.
T2  - Personalized Medicine
T1  - Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue
VL  - 13
IS  - 6
SP  - 523
EP  - 530
DO  - 10.2217/pme-2016-0032
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Demajo, Miroslav and Mandušić, Vesna and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.",
journal = "Personalized Medicine",
title = "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue",
volume = "13",
number = "6",
pages = "523-530",
doi = "10.2217/pme-2016-0032"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Demajo, M., Mandušić, V.,& Dimitrijević, B. B.. (2016). Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine, 13(6), 523-530.
https://doi.org/10.2217/pme-2016-0032
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Demajo M, Mandušić V, Dimitrijević BB. Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine. 2016;13(6):523-530.
doi:10.2217/pme-2016-0032 .
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Demajo, Miroslav, Mandušić, Vesna, Dimitrijević, Bogomir B., "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue" in Personalized Medicine, 13, no. 6 (2016):523-530,
https://doi.org/10.2217/pme-2016-0032 . .
1
1
1
1

Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Budisin, Nikola; Savovski, Kiril; Demajo, Miroslav; Dimitrijević, Bogomir B.

(2009)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Budisin, Nikola
AU  - Savovski, Kiril
AU  - Demajo, Miroslav
AU  - Dimitrijević, Bogomir B.
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2728
AB  - OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)
T2  - Analytical and Quantitative Cytology and Histology
T1  - Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source
VL  - 31
IS  - 5
SP  - 288
EP  - 295
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Budisin, Nikola and Savovski, Kiril and Demajo, Miroslav and Dimitrijević, Bogomir B.",
year = "2009",
abstract = "OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)",
journal = "Analytical and Quantitative Cytology and Histology",
title = "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source",
volume = "31",
number = "5",
pages = "288-295"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Budisin, N., Savovski, K., Demajo, M.,& Dimitrijević, B. B.. (2009). Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology, 31(5), 288-295.
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Budisin N, Savovski K, Demajo M, Dimitrijević BB. Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology. 2009;31(5):288-295..
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Budisin, Nikola, Savovski, Kiril, Demajo, Miroslav, Dimitrijević, Bogomir B., "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source" in Analytical and Quantitative Cytology and Histology, 31, no. 5 (2009):288-295.
4

Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome

Bogdanović, Gordana; Jurišić, Vladimir; Kraguljac, Nada; Mrđanović, Jasminka Ž.; Jakimov, Dimitar; Krtolica-Žikić, Koviljka; Krajnović, Milena M.; Magic, Zvonko; Stojiljković, Bratislav; Andrijevic, Ljiljana; Srdić, Tatjana; Baltic, Mirjana; Popovic, Stevan

(2007)

TY  - JOUR
AU  - Bogdanović, Gordana
AU  - Jurišić, Vladimir
AU  - Kraguljac, Nada
AU  - Mrđanović, Jasminka Ž.
AU  - Jakimov, Dimitar
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Magic, Zvonko
AU  - Stojiljković, Bratislav
AU  - Andrijevic, Ljiljana
AU  - Srdić, Tatjana
AU  - Baltic, Mirjana
AU  - Popovic, Stevan
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3219
AB  - We report on characteristics of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome (t-MDS) who had no overt post-MDS leukemia. Classic cytology analyses, immunophenotyping, cytogenetic and molecular genetic procedures were used for characterization of the cell line. PC-MDS cells are positive for the expression of CD13, CD15, CD30, CD33, and CD45 antigen. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. The karyotype analysis of PC-MDS cell line revealed various numerical and structural changes including those typically associated with t-MDS: del(5)(q13)[7], der(5)t(5;11)(p11;q11)[13], -7[6], del(7)(q31)[2], +20[3], -20[4]. Evaluation of methylation status in a promoter region of p 15, p 16 and MGMT genes showed biallelic hypermethylation pattern of 5 promoter region only in MGMT gene. PC-MDS is the first t-MDS derived cell line, and based on its immunological, cytogenetic and molecular characterization could be a new tool in evaluation of complex biology of MDS and a model for methylation studies. (c) 2007 Elsevier Ltd. All rights reserved.
T2  - Leukemia Research
T1  - Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome
VL  - 31
IS  - 8
SP  - 1097
EP  - 1105
DO  - 10.1016/j.leukres.2007.01.012
ER  - 
@article{
author = "Bogdanović, Gordana and Jurišić, Vladimir and Kraguljac, Nada and Mrđanović, Jasminka Ž. and Jakimov, Dimitar and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Magic, Zvonko and Stojiljković, Bratislav and Andrijevic, Ljiljana and Srdić, Tatjana and Baltic, Mirjana and Popovic, Stevan",
year = "2007",
abstract = "We report on characteristics of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome (t-MDS) who had no overt post-MDS leukemia. Classic cytology analyses, immunophenotyping, cytogenetic and molecular genetic procedures were used for characterization of the cell line. PC-MDS cells are positive for the expression of CD13, CD15, CD30, CD33, and CD45 antigen. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. The karyotype analysis of PC-MDS cell line revealed various numerical and structural changes including those typically associated with t-MDS: del(5)(q13)[7], der(5)t(5;11)(p11;q11)[13], -7[6], del(7)(q31)[2], +20[3], -20[4]. Evaluation of methylation status in a promoter region of p 15, p 16 and MGMT genes showed biallelic hypermethylation pattern of 5 promoter region only in MGMT gene. PC-MDS is the first t-MDS derived cell line, and based on its immunological, cytogenetic and molecular characterization could be a new tool in evaluation of complex biology of MDS and a model for methylation studies. (c) 2007 Elsevier Ltd. All rights reserved.",
journal = "Leukemia Research",
title = "Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome",
volume = "31",
number = "8",
pages = "1097-1105",
doi = "10.1016/j.leukres.2007.01.012"
}
Bogdanović, G., Jurišić, V., Kraguljac, N., Mrđanović, J. Ž., Jakimov, D., Krtolica-Žikić, K., Krajnović, M. M., Magic, Z., Stojiljković, B., Andrijevic, L., Srdić, T., Baltic, M.,& Popovic, S.. (2007). Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. in Leukemia Research, 31(8), 1097-1105.
https://doi.org/10.1016/j.leukres.2007.01.012
Bogdanović G, Jurišić V, Kraguljac N, Mrđanović JŽ, Jakimov D, Krtolica-Žikić K, Krajnović MM, Magic Z, Stojiljković B, Andrijevic L, Srdić T, Baltic M, Popovic S. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. in Leukemia Research. 2007;31(8):1097-1105.
doi:10.1016/j.leukres.2007.01.012 .
Bogdanović, Gordana, Jurišić, Vladimir, Kraguljac, Nada, Mrđanović, Jasminka Ž., Jakimov, Dimitar, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Magic, Zvonko, Stojiljković, Bratislav, Andrijevic, Ljiljana, Srdić, Tatjana, Baltic, Mirjana, Popovic, Stevan, "Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome" in Leukemia Research, 31, no. 8 (2007):1097-1105,
https://doi.org/10.1016/j.leukres.2007.01.012 . .
7
9
9

Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients

Ivanović, Vesna; Demajo, Miroslav; Krtolica-Žikić, Koviljka; Krajnović, Milena M.; Dimitrijević, Bogomir B.; Konstantinovic, M.; Baltic, Vladimir; Prtenjak, Gordana; Stojiljković, Bratislav; Breberina, Milan; Nešković-Konstantinović, Zora; Nikolic-Vukosavljevic, Dragica

(2006)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Konstantinovic, M.
AU  - Baltic, Vladimir
AU  - Prtenjak, Gordana
AU  - Stojiljković, Bratislav
AU  - Breberina, Milan
AU  - Nešković-Konstantinović, Zora
AU  - Nikolic-Vukosavljevic, Dragica
PY  - 2006
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3079
AB  - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
T2  - Clinica Chimica Acta
T1  - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
VL  - 371
IS  - 1-2
SP  - 191
EP  - 193
DO  - 10.1016/j.cca.2006.02.027
ER  - 
@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltic, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolic-Vukosavljevic, Dragica",
year = "2006",
abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.",
journal = "Clinica Chimica Acta",
title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients",
volume = "371",
number = "1-2",
pages = "191-193",
doi = "10.1016/j.cca.2006.02.027"
}
Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltic, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolic-Vukosavljevic, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193.
https://doi.org/10.1016/j.cca.2006.02.027
Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltic V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolic-Vukosavljevic D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193.
doi:10.1016/j.cca.2006.02.027 .
Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltic, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolic-Vukosavljevic, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193,
https://doi.org/10.1016/j.cca.2006.02.027 . .
50
54
56